BLCM Bellicum Pharmaceuticals Inc (PK)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Foster Aaron E.	2. Issuer Name and Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC [ BLCM ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Sr VP, Head of Research
(Last)          (First)          (Middle) C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800	3. Date of Earliest Transaction (MM/DD/YYYY) 1/2/2020
(Street) HOUSTON, TX 77030 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	1/2/2020		M		2500	A	(1)	7834 (2)	D
Common Stock	1/2/2020		F(3)		942	D	$1.51	6892	D
Common Stock	1/3/2020		M		625	A	(1)	7517	D
Common Stock	1/3/2020		F(4)		236	D	$1.40	7281	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	1/2/2020		M			2500	(5)	(5)	Common Stock	2500.0	$0	5000	D
Restricted Stock Units	(1)	1/3/2020		M			625	(6)	(6)	Common Stock	625.0	$0	625	D

Explanation of Responses:
(1)	Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock.
(2)	Includes 1,597 shares acquired by the reporting person under the Issuer's Employee Stock Purchase Plan.
(3)	Represents the number of shares withheld by and surrendered to the Issuer on January 2, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted to the reporting person on January 2, 2018 for 10,000 shares.
(4)	Represents the number of shares withheld by and surrendered to the Issuer on January 3, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted to the reporting person on January 3, 2017 for 2,500 shares.
(5)	On January 2, 2018, the reporting person was granted 10,000 RSUs, of which 2,500 vested on January 2, 2020. The RSUs vest in four annual installments beginning on January 2, 2019.
(6)	On January 3, 2017, the reporting person was granted 2,500 RSUs, of which 625 vested on January 3, 2020. The RSUs vest in four annual installments beginning on January 3, 2018.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Foster Aaron E. C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800 HOUSTON, TX 77030			Sr VP, Head of Research

Signatures
/s/ Aaron E. Foster		1/6/2020
**Signature of Reporting Person		Date